In last trading session, Atossa Therapeutics Inc (NASDAQ:ATOS) saw 0.39 million shares changing hands with its beta currently measuring 1.45. Company’s recent per share price level of $0.72 trading at $0.03 or 5.00% at ring of the bell on the day assigns it a market valuation of $90.53M. That closing price of ATOS’s stock is at a discount of -220.83% from its 52-week high price of $2.31 and is indicating a premium of 8.33% from its 52-week low price of $0.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.52 million shares which gives us an average trading volume of 748.12K if we extend that period to 3-months.
For Atossa Therapeutics Inc (ATOS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.06 in the current quarter.
Atossa Therapeutics Inc (NASDAQ:ATOS) trade information
Upright in the green during last session for gaining 5.00%, in the last five days ATOS remained trading in the red while hitting it’s week-highest on Tuesday, 03/11/25 when the stock touched $0.72 price level, adding 5.7% to its value on the day. Atossa Therapeutics Inc’s shares saw a change of -23.77% in year-to-date performance and have moved -2.43% in past 5-day. Atossa Therapeutics Inc (NASDAQ:ATOS) showed a performance of -6.36% in past 30-days. Number of shares sold short was 8.86 million shares which calculate 13.82 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 85.6% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -594.44% in reaching the projected high whereas dropping to the targeted low would mean a loss of -594.44% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 46.61% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 9.72% while estimates for its earnings growth in next 5 years are of -8.91%.
Atossa Therapeutics Inc (NASDAQ:ATOS)’s Major holders
Insiders are in possession of 0.06% of company’s total shares while institution are holding 28.55 percent of that, with stock having share float percentage of 28.57%. Investors also watch the number of corporate investors in a company very closely, which is 28.55% institutions for Atossa Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ATOS for having 9.2 million shares of worth $10.94 million. And as of 2024-06-30, it was holding 7.3389 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 6.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.1755 of outstanding shares, having a total worth of $7.72 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.94 shares of worth $2.84 million or 3.13% of the total outstanding shares. The later fund manager was in possession of 3.43 shares on Dec 31, 2024 , making its stake of worth around $2.47 million in the company or a holder of 2.73% of company’s stock.
